All News

PSO.Palmoplantar.jpg

Deucravacitinib in Psoriasis - 5 Year Outcomes

Jack Cush, MD

BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr.

Read Article
cost.price_.drugs_.pills_.jpg

The Cartel is Coming for Rheumatology

Eric Dein, MD

"What Do Blockbuster Drugs & The Black Market All Have in Common?" asked Dr. Madelaine Feldman at RheumNow Live 2025. They thrive, she explained, on market exclusivity "... until they don't." At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.

Read Article
Kavanaugh RNL 25

Combination biologics in PsA: are we there yet?

Adela Castro, MD

Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.

Read Article
psoriasis,arm,hand,rash,elbow

“Preventing” Arthritis in Psoriasis

Richard Conway, MBBChBAO, PhD

The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.

Read Article
RheumNow Podcast square

Drug Naming Games (2.7.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.

Read Article
synovitis2.JPG

Granzyme - a major driver of inflammatory & autoimmune diseases

EurekAlert!

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury.

Read Article
Deucravacitinib in Psoriasis - 5 Year Outcomes BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter… https://t.co/as7QR8RTyx https://t.co/yNluBPR7fO
Dr. John Cush RheumNow ( View Tweet)
Combination biologics in PsA: are we there yet? Combination therapy is well-established in rheumatoid arthritis, but its efficacy in psoriatic arthritis (PsA) remains uncertain. Despite effective treatment options, there is a need for solutions for patients unresponsive to… https://t.co/uqLnxLIktM https://t.co/awwaVPOZTu
Dr. John Cush RheumNow ( View Tweet)
“Preventing” Arthritis in Psoriasis Prevention of the development of our systemic rheumatic diseases in individuals deemed at risk, or with some form of precursor disease process, has been a hot topic in recent years. https://t.co/nGKGUkKVUl https://t.co/PruJZLAq9n

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o

Links:

Dr. John Cush RheumNow ( View Tweet)
New for HS - Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2 - Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE) Clinical trials: IL23 failed, ILalpha failed Brodulamab (IL17a) clinically meaningful response TNF trials @RheumNow #ACR2025 https://t.co/BfzwNQ1wUB

Links:

Eric Dein ericdeinmd ( View Tweet)
1/3 of #axial #PsA 👇 No #SI joint changes , only #axial ⁦@RheumNow⁩ #RNL2025 Catherine Blackwell #ClinicalPearl https://t.co/YmoipL1bME

Links:

Janet Pope Janetbirdope ( View Tweet)
P2 Trial: DEU in PsA Encouraging results for DCV 6 and 12 mg qd. ACR20 63% for DCV 12 mg (p=0.0004) Not yet FDA approved for PsA, only PsO Pending P3 P2: DEU in SLE - PAISLEY Improved SRI(4), CLASI-50 at w32 Merola #RNL2025 @RheumNow https://t.co/RV7OPaZWjx

Links:

Eric Dein ericdeinmd ( View Tweet)
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95

Links:

Richard Conway RichardPAConway ( View Tweet)
#HOT #topic Will #Rx of #PsO PREVENT onset of #PsA Well, maybe 🤔 Alexis R Ogdie ⁦@RheumNow⁩ #RNL2025 70% of #psoriatic #arthritis is preceded by #psoriasis Still a bit of a debate re prevention of PsA https://t.co/7bce8kcjdr

Links:

Janet Pope Janetbirdope ( View Tweet)
Risk factors for development of PsA in psoriasis. Psoriasis severity, obesity, and depression. @alexisogdie @RheumNow @RNL2025 https://t.co/obMDBvLLnx

Links:

Richard Conway RichardPAConway ( View Tweet)
Great graph from @AlexisOgdie on the effect of biologic treatment on PsA development in psoriasis. Obvious front-loading in those who need systemic therapy. But over time those who don't appear to develop more PsA @RheumNow @RNL2025 https://t.co/UxUZyKb0NA

Links:

Richard Conway RichardPAConway ( View Tweet)
Can treatment of PsO prevent PsA? -Severity of PsO and obesity->Risk fx for PsA -PRESTO scores: Predicts whether you will develop PsA in the next year vs next 5 years -Does ttx of PsO impact development of PsA? Trials are mostly observational (several confounders) TriNetX data:… https://t.co/TBv3Y2TLZv https://t.co/1K0MtMQ5gn

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Predicting #PsA PRESTO study #obvious risks are #predictive Alexis R Ogdie ⁦@RheumNow⁩ #RNL2025 bad PsO 2X ^PsA High BMI Depression Modifiable risks #psoriasis #psoriatic #arthritis https://t.co/pOxidCWcg5

Links:

Janet Pope Janetbirdope ( View Tweet)
QD Clinic - New Palmoplantar Psoriasis and PsA New Onset Palmoplantar PsO and PsA - what are the options? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6… https://t.co/3ubBL6HVGF https://t.co/Zdd6Dih5eZ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×